Search hospitals > California > Los Angeles
Jonsson Comprehensive Cancer Center, UCLA
Claim this profileLos Angeles, California 90095
Global Leader in Cancer
Global Leader in Leukemia
Conducts research for Breast Cancer
Conducts research for Lymphoma
Conducts research for Brain Tumor
725 reported clinical trials
43 medical researchers
Summary
Jonsson Comprehensive Cancer Center, UCLA is a medical facility located in Los Angeles, California. This center is recognized for care of Cancer, Leukemia, Breast Cancer, Lymphoma, Brain Tumor and other specialties. Jonsson Comprehensive Cancer Center, UCLA is involved with conducting 725 clinical trials across 528 conditions. There are 43 research doctors associated with this hospital, such as Zev A. Wainberg, William A. May, Theodore Moore, MD, and Bartosz Chmielowski, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Leukemia
Global LeaderStage II
Stage I
HLA-A positive
Top PIs
Zev A. WainbergUCLA2 years of reported clinical research
Expert in Solid Tumors
Studies Pancreatic Cancer
32 reported clinical trials
64 drugs studied
William A. MayMattel Children's Hospital UCLA7 years of reported clinical research
Expert in Tumors
Studies Brain Tumor
23 reported clinical trials
59 drugs studied
Theodore Moore, MDMattel Children's Hospital UCLA7 years of reported clinical research
Studies Tumors
Studies Cancer
21 reported clinical trials
59 drugs studied
Bartosz Chmielowski, MDUCLA2 years of reported clinical research
Expert in Melanoma
Studies Skin Cancer
17 reported clinical trials
31 drugs studied
Clinical Trials running at Jonsson Comprehensive Cancer Center, UCLA
Breast Cancer
Prostate Cancer
Cancer
Renal Cell Carcinoma
Bladder Carcinoma
Diffuse Large B-Cell Lymphoma
Lung Cancer
Bladder Cancer
Rectal Cancer
Lymphoma
IL13Ralpha2 CAR T Cells
for Advanced Skin Cancer
This trial tests the safety and best dose of modified immune cells for patients with advanced melanoma or other cancers that have spread. The treatment uses the patient's own T cells, which are changed in a lab to better attack cancer cells. The goal is to see if these modified cells can safely and effectively fight the cancer.
Recruiting1 award Phase 113 criteria
Triple Drug Therapy
for HER2 Positive Breast Cancer
This phase Ib/II trial studies the side effects and best dose of ribociclib, tucatinib, and trastuzumab for the treatment of HER2 positive breast cancer that has spread to other parts of the body (metastatic), and then compares the effect of ribociclib, tucatinib, trastuzumab with or without fulvestrant to docetaxel, carboplatin, trastuzumab, and pertuzumab (standard of care) for the treatment of early stage breast cancer before surgery (neoadjuvant therapy). Ribociclib and tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Pertuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Estrogen can cause the growth of breast tumor cells. Fulvestrant blocks the use of estrogen by the tumor cells. Chemotherapy drugs, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ribociclib, tucatinib, and trastuzumab with or without fulvestrant before surgery may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed.
Recruiting1 award Phase 1 & 220 criteria
FAPi & PSMA PET/CT Imaging
for Cancer Detection
This phase I trial studies a new imaging technique called FAPi PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulate in normal and cancer tissues in patients with non-prostate cancer. The research team also want to know whether what they see on PET/CT images represents the tumor tissue being excised from the patient's body. The research team is also interested to investigate another new imaging technique called PSMA PET/CT. Participants will be invited to undergo another PET/CT scan, with the PSMA tracer (68Ga-PSMA-11). This is not required but just an option for volunteer patients. Patients who have not received an 18F-FDG PET/CT within one month of enrollment will also undergo an FDG PET/CT scan. The PET/CT scanner combines the PET and the CT scanners into a single device. This device combines the anatomic (body structure) information provided by the CT scan with the metabolic information obtained from the PET scan. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of, in the case of this research, 68Ga-PSMA-11 and 68Ga-FAPi, and 18F-FDG (if applicable). Because some cancers take up 68Ga-PSMA-11 and/or 68Ga-FAPi it can be seen with PET. CT utilizes x-rays that traverse the body from the outside. CT images provide an exact outline of organs where it occurs in patient's body. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors. The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers. PSMA stands for Prostate Specific Membrane Antigen. This name is incorrect as PSMA is also found in many other cancers. The function of PSMA is not well understood but imaging studies have shown that PSMA can be detected with PET in many non-prostate cancers. Imaging FAP with PET/CT may in the future provide additional information about various cancers.
Recruiting1 award Phase < 15 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Jonsson Comprehensive Cancer Center, UCLA?
Jonsson Comprehensive Cancer Center, UCLA is a medical facility located in Los Angeles, California. This center is recognized for care of Cancer, Leukemia, Breast Cancer, Lymphoma, Brain Tumor and other specialties. Jonsson Comprehensive Cancer Center, UCLA is involved with conducting 725 clinical trials across 528 conditions. There are 43 research doctors associated with this hospital, such as Zev A. Wainberg, William A. May, Theodore Moore, MD, and Bartosz Chmielowski, MD.
Where is Jonsson Comprehensive Cancer Center, UCLA located?
**UCLA Jonsson Comprehensive Cancer Center**
- **Address:** 10833 Le Conte Ave, Los Angeles, CA 90024
- **Directions:** From the east, take the 10 (Santa Monica Freeway) east to 405 (San Diego Freeway) north. Exit on Wilshire Blvd east to reach the center.
Who should I call to ask about financial aid or insurance network?
Jonsson Comprehensive Cancer Center, UCLA Hospital Financial Assistance and Insurance Departments:
**Financial Assistance:**
- Julia Leavitt, Financial Counselor: [email protected]
- UCLA Health Financial Assistance Program: 310-825-8021 (Monday through Friday, 8:30 am to 4:00 pm)
**Insurance:**
- Jay Russell, Insurance Officer: jrussell@ashe.ucla.edu
- Adrian Martinez, Insurance Officer: amartinez@ashe.ucla.edu
What insurance does Jonsson Comprehensive Cancer Center, UCLA accept?
The UCLA Jonsson Comprehensive Cancer Center accepts most health insurance plans, including Medicare, and most HMO and PPO insurance, billing directly for covered services. It's advised to confirm your coverage with your benefits coordinator or health insurance company, as accepted plans may change.
What awards or recognition has Jonsson Comprehensive Cancer Center, UCLA received?
The Jonsson Comprehensive Cancer Center at UCLA is designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI), highlighting its excellence in research, education, and patient care. It is renowned for groundbreaking discoveries, including the development of Herceptin for breast cancer and Keytruda for metastatic melanoma. The Center is also committed to community outreach, health disparities research, and the development of supportive cancer care and survivorship programs.